Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis
Liwen Li, … , Gutian Xiao, Zhaoxia Qu
Liwen Li, … , Gutian Xiao, Zhaoxia Qu
Published February 4, 2021
Citation Information: JCI Insight. 2021;6(5):e144394. https://doi.org/10.1172/jci.insight.144394.
View: Text | PDF
Research Article Oncology

PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis

  • Text
  • PDF
Abstract

One of the most fundamental and challenging questions in the field of cancer is how immunity is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identified the tumor suppressor PDZ-LIM domain–containing protein 2 (PDLIM2) as a checkpoint of alveolar macrophages (AMs) important for lung tumor suppression. During lung tumorigenesis, PDLIM2 expression in AMs is downregulated by ROS-activated transcription repressor BTB and CNC homology 1 (BACH1). PDLIM2 downregulation leads to constitutive activation of the transcription factor STAT3, driving AM protumorigenic polarization/activation and differentiation from monocytes attracted from the circulation to suppress cytotoxic T lymphocytes and promote lung cancer. PDLIM2 downregulation also decreases AM phagocytosis. These findings establish ROS/BACH1/PDLIM2/STAT3 as a signaling pathway driving AMs for lung tumor promotion.

Authors

Liwen Li, Fan Sun, Lei Han, Xujie Liu, Yadong Xiao, Alyssa D. Gregory, Steven D. Shapiro, Gutian Xiao, Zhaoxia Qu

×

Figure 5

Pathogenic and clinical relevance of PDLIM2 repression in AMs.

Options: View larger image (or click on image) Download as PowerPoint
Pathogenic and clinical relevance of PDLIM2 repression in AMs.
(A) qPCR ...
(A) qPCR showing decreased Pdlim2 expression in BAL cells during lung tumorigenesis (n ≥ 3); 18S rRNA was used as internal control. (B and C) IF and IHC analysis showing decreased PDLIM2 expression in AMs in urethane-treated mice (n ≥ 3). Arrows indicate AMs. Scale bar: 20 μm. (D) IHC analysis showing decreased PDLIM2 in AMs around human lung cancers compared with those in matched normal human lung tissues (n = 4). Arrows indicate AMs. Scale bar: 20 μm. (E) Kaplan-Meier survival curve showing a positive association between pulmonary macrophage PDLIM2 expression levels and overall survival of patients with lung cancer in lung cancer tissue microarray. Ordinary 1-way ANOVA (A), Student’s t test (2 tailed, unpaired) (B–D), and Gehan-Breslow-Wilcoxon test (E) were performed. Data represent mean ± SEM in A–D. *P < 0.05; **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts